

Why attend a Guidelines Forum®?

- The development and successful implementation of guidelines requires both communication and transparency between all stakeholders. The Guidelines Forum is a closed workshop during which meaningful discussions occur between academic faculty members covering relevant topics for industry attendees.
- A better understanding of the processes involved in guidelines development and implementation will help attendees that develop drugs, biomarkers and devices, to adapt and improve their research and development programs for the future.
- Case based discussions: the success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development.
- Guidelines really shape clinical practice if doctors and their patients adopt them. Therefore, implementation is essential. This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

Who should attend?

Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.

SOME OF THE CONFIRMED EXPERTS:

- Pierre Amarenco, Paris, France
- Mayank Goyal, Calgary, Canada
- Paulus Kirchhof, Birmingham, UK
- Thorsten Lewalter, Munich, Germany
- George Ntaios, Larissa, Greece
- Tatjana S. Potpara, Belgrade, Serbia
- Horst Sievert, Frankfurt, Germany
- Thorsten Steiner, Heidelberg, Germany
- Götz Thomalla, Hamburg, Germany
- Freek Verheugt, Amsterdam, The Netherlands

Conditions of sales

Cancellation Fees will apply as of receipt of the confirmation for sponsorships and registrations as follows:

- 10% from 26 August 2016 to 31 October 2016
- 50% from 01 November 2016 to 31 January 2017
- 100% from 01 February 2017

Contact us

TMA Foundation
Email: info@tmacademy.org

Grant Opportunities (including CME, Advisory Boards & Customized Grants)

William Melhuish / Yann Colardelle
Tel.: + 33 (0) 6 16 54 81 57
E-mail: william@mededgs.com and
yanncol@tmacademy.org

Registration : www.tmacademy.org

Agenda

6th & 7th
April
2017

1st edition

Munich
Germany

Stroke Prevention and Management Guidelines Forum

Better understand the stroke
guidelines development process
and its implications

GUIDELINES
FORUM
Stroke



Preliminary Agenda

Stroke Prevention and Management

The objective is to better understand the existing stroke guidelines development process and its implications in clinical practice. It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines.

Clinical practice guidelines and associated implementation strategies are essential to

promote optimal, evidence-based practices in stroke prevention and management. While current practice guidelines are generally in agreement, specific recommendations may differ, reflecting diverging interpretations of the available evidence or the lack of sufficient data to make evidence-based recommendations. In addition, a number of questions arise as a result of a rapidly changing clinical landscape and attempts at addressing unmet clinical needs.

Draft Agenda

- Welcome and introduction
- Methodological issues in clinical practice guideline development
 - » Selection of working group members
 - » Systematic literature review and evidence tables
 - » The process from evidence to recommendations
 - » Levels of evidence and strengths of recommendations
 - » Managing conflicts of interest

Early Management of Patients with Acute Ischaemic Stroke

- Emergency imaging in patients with acute ischaemic stroke
 - » Information needed before any specific treatment is initiated: current recommendations
 - » Wake-up stroke
 - » What do we expect from additional imaging paradigms (CT perfusion and CTA, MRI perfusion or diffusion imaging)?
- Medical treatment in the early management of acute ischemic stroke: thrombolysis
 - » Debated criteria for treatment: timing (3 h, 4.5 h, 6h?), age (<80 years?), the diabetic patient, antithrombotic treatment and antidotes
- Endovascular treatment of acute ischemic stroke: stent retrievers and other thrombectomy/aspiration devices
 - » Eligibility criteria and prehospital patient selection
 - » Timing
- Stroke care: organizational aspects to reduce time to treatment
 - » Reducing pre-hospital and in-hospital delays: can we make evidence-based recommendations?

Prevention of Stroke in Patients with Large Artery Atherosclerosis

- Cryptogenic stroke and embolic stroke of undetermined source (ESUS)
 - » Unknown causes of cerebral infarcts: diagnostic approaches and therapeutic options
 - » Detection of occult atrial fibrillation
- Prevention of early recurrent stroke after TIA or minor stroke: medical and organizational aspects
- Role of new antiplatelet agents for stroke prevention in patients with non-cardioembolic stroke
 - » Can we expect a net clinical improvement due to a more potent effect in comparison with established antiplatelet agents?
- Oral anticoagulants versus antiplatelet agents for prevention of stroke/TIA in patients with large artery atherosclerosis
 - » Extracranial and intracranial stenosis
 - » Are NOACs a game changer?
- Interventional approaches: where do we stand?
 - » Carotid endarterectomy (CEA) versus carotid angioplasty and stenting (CAS)
 - » Extracranial-intracranial bypass

Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation

- Evaluation of stroke and bleeding risks in patients with AF – where do we stand?
- Stroke risk stratification and indications for anticoagulant treatment
 - » Is there a consensus on the CHA2DS2-VASc score?
 - » Identifying AF patients at low risk of stroke in whom oral anticoagulation is not recommended
- Bleeding risk assessment
 - » Risk scores, role of selected biomarkers
 - » Appropriate clinical use of bleeding risk scores
- Which anticoagulant treatment to prevent stroke in AF?
 - » VKAs vs NOACs
 - » Which NOAC for which patient?
 - » Real-world evidence vs clinical trials
 - » Advances in the development of reversal agents
- » Nonpharmacological options for stroke prevention in AF
 - » LAA occlusion
 - » LAA occlusion or excision concomitant to cardiac surgery
 - » Patient selection: lack of clear consensus
- Patients with AF and clinically apparent CAD undergoing PCI with stenting
 - » What are currently the optimal antithrombotic strategies (which combination, which duration)?
 - » PIONEER AF-PCI and ongoing trials

CO-CHAIRS

Prof. Hans-Christoph Diener

MD, PhD, FAHA, FAAN
Senior Professor for Clinical Neurosciences - Department of Neurology University Duisburg-Essen, Germany



Prof. Stuart J. Connolly

MD, FRCP(C)
Professor of Medicine at McMaster University and a Cardiac Electrophysiologist at Hamilton Health Sciences Canada

